Hennion & Walsh Asset Management Inc. Makes New $1.74 Million Investment in Fulgent Genetics, Inc. $FLGT

Hennion & Walsh Asset Management Inc. acquired a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 66,190 shares of the company’s stock, valued at approximately $1,739,000. Hennion & Walsh Asset Management Inc. owned about 0.21% of Fulgent Genetics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of FLGT. Rhumbline Advisers grew its stake in shares of Fulgent Genetics by 2.4% during the second quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock worth $659,000 after purchasing an additional 785 shares in the last quarter. Mackenzie Financial Corp raised its stake in Fulgent Genetics by 11.2% in the third quarter. Mackenzie Financial Corp now owns 12,155 shares of the company’s stock valued at $275,000 after buying an additional 1,220 shares in the last quarter. Peapod Lane Capital LLC raised its stake in Fulgent Genetics by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 164,579 shares of the company’s stock valued at $3,720,000 after buying an additional 1,810 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Fulgent Genetics by 2.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 87,318 shares of the company’s stock worth $1,736,000 after buying an additional 2,128 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Fulgent Genetics during the 2nd quarter worth about $49,000. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Fulgent Genetics Trading Up 3.4%

Shares of FLGT opened at $16.44 on Thursday. The company’s 50 day simple moving average is $20.13 and its 200-day simple moving average is $23.79. The firm has a market cap of $513.42 million, a PE ratio of -8.39 and a beta of 0.89. Fulgent Genetics, Inc. has a 12-month low of $13.46 and a 12-month high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings results on Friday, February 27th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.02 by $0.14. Fulgent Genetics had a negative net margin of 18.75% and a negative return on equity of 2.22%. The firm had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. As a group, equities research analysts forecast that Fulgent Genetics, Inc. will post -0.85 EPS for the current fiscal year.

Analysts Set New Price Targets

FLGT has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Zacks Research cut Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $32.00.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.